STOCK TITAN

Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference

Fate Therapeutics (NASDAQ: FATE) announced management will participate in the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 in Miami, Florida.

(Neutral)
(Neutral)
Tags

Fate Therapeutics (NASDAQ: FATE) announced management will participate in the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 in Miami, Florida.

Management will join a fireside chat at 9:20 AM ET, host investor meetings, and provide a live webcast with an archived replay available for 90 days.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.
Argus Mar 4 session
+5.84% close to close Open Argus
Details

News Market Reaction – FATE

In the Mar 4 session, FATE gained 5.84%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.8% in the session following this news. A strong positive reaction aligns with Fat...
Analysis

The stock moved +5.8% in the session following this news. A strong positive reaction aligns with Fate’s position above its 200-day MA of $1.17 and within the upper half of its 52-week range, with shares at $1.50. Historically, even solid clinical updates produced only modest moves, and one key data release saw a -0.93% divergence. Investors have also seen frequent conference appearances as neutral. Any extended strength could eventually confront prior dilution-free capital needs and insider sell-to-cover activity as potential overhangs.

Key Figures

Conference date: March 9, 2026 Fireside chat time: 9:20 AM ET Webcast replay period: 90 days +5 more
Conference date
March 9, 2026
Leerink Partners 2026 Global Healthcare Conference
Fireside chat time
9:20 AM ET
Scheduled management fireside chat
Webcast replay period
90 days
Archived replay available on company website
Current price
$1.50
Pre-news trading level
52-week high
$1.9399
Upper end of 52-week trading range
52-week low
$0.6611
Lower end of 52-week trading range
Price vs 52-week high
-22.68%
Distance from 52-week high before this news
Market cap
$170,721,388
Equity value prior to conference announcement

Historical Context

5 past events · Latest: Feb 26
5 events
  1. Feb 26

    Earnings and update

    24h Move
    +5.4%

    Q4 and 2025 results with strong cash and reduced operating expenses.

  2. Feb 03

    Inducement awards

    24h Move
    -0.9%

    New-hire stock options and RSUs under Nasdaq inducement rule.

  3. Jan 05

    Inducement awards

    24h Move
    +0.0%

    Equity awards to new hires via options and RSUs for recruitment.

  4. Dec 08

    Clinical data update

    24h Move
    -0.9%

    Updated Phase 1 FT819 data and preclinical advances for FT836/FT839.

  5. Nov 25

    Conference presentation

    24h Move
    -1.9%

    Participation in Piper Sandler healthcare conference with fireside chat.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

induced pluripotent stem cell, cellular immunotherapies, webcast
3 terms
induced pluripotent stem cell medical
"a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular"
Cells taken from an adult (such as skin or blood) that scientists ‘reprogram’ so they behave like versatile early-stage cells capable of becoming many different cell types in the body. For investors, these cells matter because they enable development of personalized therapies, safer and faster drug testing, and potential regenerative treatments—like resetting a gadget to factory mode so it can run many different apps—creating new commercial opportunities and affecting biotech valuation and risk.
cellular immunotherapies medical
"iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune"
Cellular immunotherapies are medical treatments that use living immune cells, taken from a patient or donor and then trained, modified, or expanded in a lab so they better recognize and attack disease, such as cancer or infection. For investors, these therapies matter because they can offer dramatic, durable patient responses and premium pricing but also carry high development, manufacturing and regulatory risks—think of them as highly trained sniffer dogs that can be powerful but expensive and complex to deploy.
webcast technical
"A live webcast of the fireside chat can be accessed under “Events"
A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in a fireside chat and host investor meetings at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 in Miami, Florida.

Management will participate in a fireside chat at 9:20 AM ET on Monday, March 9. A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. An archived replay of the webcast will be available for 90 days on the Company’s website following the event.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:

Ryan Douglas
Fate Therapeutics, Inc.
IR@fatetherapeutics.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Fate Therapeutics (FATE) present at the Leerink Partners 2026 Global Healthcare Conference?

Fate Therapeutics will present on Monday, March 9, 2026 at 9:20 AM ET. According to the company, management will participate in a fireside chat and host investor meetings during the conference in Miami.

How can investors watch the Fate Therapeutics (FATE) fireside chat webcast on March 9, 2026?

Investors can watch the live webcast via the company website under Events & Presentations. According to the company, the webcast is accessible in the Investors section at www.fatetherapeutics.com.

Will the Fate Therapeutics (FATE) webcast from the Leerink 2026 conference be available after the event?

Yes, an archived replay will be available for 90 days following the event. According to the company, the replay will be posted on the company website in the Investors Events & Presentations area.

What topics will Fate Therapeutics (FATE) management cover at the Leerink Partners 2026 conference?

Management will participate in a fireside chat and investor meetings, focusing on company developments and strategy. According to the company, the session is intended to update investors on recent program progress and corporate direction.

Where is the Leerink Partners 2026 Global Healthcare Conference taking place for Fate Therapeutics (FATE)?

The conference is in Miami, Florida on Monday, March 9, 2026. According to the company, Fate Therapeutics management will attend in-person to meet investors and participate in the scheduled fireside chat.

Keep reading